cas 444289-05-8|| where to buy 3-[7-(aminomethyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride

Название продукции:3-[7-(aminomethyl)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione;hydrochloride

IUPAC Name:3-[4-(aminomethyl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione hydrochloride

: CAS：444289-05-8; Молекулярная формула：C14H16ClN3O3; Чистота：95%+

Упаковочная единица	Доступно для заказа	Цена ($)
CM340808-100mg	in stock	ưƄź
CM340808-250mg	in stock	ŢƄǯ
CM340808-1g	in stock	ǯưǯ
CM340808-5g	in stock	ŢŢŢź

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 444289-05-8 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:444289-05-8; Молекулярная формула:C14H16ClN3O3; Точка плавления:-; Smiles-код:O=C(C(N1CC2=C(C=CC=C2CN)C1=O)CC3)NC3=O.[H]Cl; Плотность:

: Номер в каталоге:CM340808; Молекулярная масса:309.75; Точка кипения:; Номер Mdl:; Хранение:

: PROTAC-E3 Ligase Ligands; Bifunctional degrader molecules, also called proteolysis-targeting chimeras (PROTACs), are a new modality of chemical tools and potential therapeutics to understand and treat human disease. A required PROTAC component is a ligand binding to an E3 ubiquitin ligase, which is then joined to another ligand binding to a protein to be degraded via the ubiquitin–proteasome system. The advent of nonpeptidic small-molecule E3 ligase ligands revolutionized the field and ushered in the design of drug-like PROTACs with potent and selective degradation activity.; PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; Proteolysis-Targeting Chimeras | PROTAC-E3 Ligase Ligands | PROTACs | Bifunctional Degrader Molecules; PROTAC (Proteolysis-Targeting Chimeras) is a promising approach in drug discovery that involves the use of small molecules to target specific proteins for degradation by the cellular machinery.